Eurican Dhppi - 1ml x10

A live vaccine against canine infectious tracheobronchitis caused by B. bronchiseptica and parainfluenza virus in dogs. Infectious tracheobronchitis is a highly contagious, multi-factorial disease of the dog’s respiratory tract. Bordetella bronchiseptica and canine parainfluenza are the most common bacterial and viral agents associated with the disease. Environmental factors such as stress, ventilation and climate may also contribute. Nobivac KC is a low volume dose (0.4ml), easy to administer, intranasal vaccine which acts against both the key causative agents of infectious tracheobronchitis and provides protection within 72 hours and lasts for at least 12 months. It can be used in puppies as young as three weeks and in pregnant bitches.

Indications for use Active immunisation of dogs to: -prevent mortality, clinical signs, infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae -prevent mortality* and clinical signs, reduce infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Canicola serovar Canicola. -prevent mortality*, and reduce clinical signs, infection, bacterial excretion renal carriage and renal lesions caused by Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa. - prevent mortality, clinical signs, renal infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni.** Onset of immunity: 2 weeks after the second injection of the primary vaccination course for all strains Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains * For Leptospira Canicola and Grippotyphosa, no mortality occurred during challenge experiment for duration of immunity. ** For Leptospira Copenhageni the duration of immunity was not establishedIndications for use Active immunisation of dogs to: -prevent mortality, clinical signs, infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae -prevent mortality* and clinical signs, reduce infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Canicola serovar Canicola. -prevent mortality*, and reduce clinical signs, infection, bacterial excretion renal carriage and renal lesions caused by Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa. - prevent mortality, clinical signs, renal infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni.** Onset of immunity: 2 weeks after the second injection of the primary vaccination course for all strains Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains * For Leptospira Canicola and Grippotyphosa, no mortality occurred during challenge experiment for duration of immunity. ** For Leptospira Copenhageni the duration of immunity was not established

Ideal for veterinary, equine and livestock farming industry

For the treatment of canine congestive heart failure originating from valvular insufficiency (mitral and/or tricuspid regurgitation) or dilated cardiomyopathy. Active ingredient: Pimobendan